A phase 1 clinical trial investigating a naked plasmid DNA vaccine in metastatic BC patients is currently ongoing (NCT02204098) and preliminary evidence suggested an increased specific CD8+ T-cell proliferation and cytotoxicity along with an improved PFS rate (116). The gene discussed is CD8A; the disease is breast cancer.